Drugs for cancer and alcoholism show promise for RP
With all the interest in exciting gene and cell therapies for inherited sight loss, it’s easy to forget that more traditional drugs can also hold promise.
Search
Search results
Flipping the switch on RP: SparingVision doses patients in their first in-human clinical trial for SPVN20
The latest research news from Retina UK.
Belite Bio announces promising phase 3 results for Stargardt disease
The latest research news from Retina UK.
Joint statement on benefits and employment support
As a coalition of sight loss charities, we are calling on the Government to make the benefit system and employment support fit for purpose for blind and partially sighted people.
Edinburgh Local Peer Support Group
Saturday 11 April 2026, 11.00am - 1.00pm - In-person - Come and join Valerie and the group for our first meeting of 2026 when we return to the Festival Theatre, Edinburgh to hear from guest speaker Chloe Brotherton, PhD Student working with Dr Roly Megaw.
Berkshire Local Peer Support Group
Monday 30 March 2026, 7.00pm - 8.00pm - Via Zoom - Come and join James and the group for their latest online social catch up.
Manchester Local Peer Support Group
Saturday 21 March 2026, 3.00pm - 8.00pm - In-person - Come and join Rachael and the group for their latest in-person meeting at The Waldorf pub for a social get together and catch up.
Opus genetics launches clinical trial for MERTK-related retinitis pigmentosa
Opus Genetics has launched an early-stage clinical trial of OPGx-MERTK, an investigational gene therapy for MERTK-related Retinitis Pigmentosa (RP), a condition that causes progressive vision loss due to photoreceptor degeneration.
For professionals
Information for healthcare professionals: Genetic testing and counselling in inherited retinal disease
Research update – ProQR
In February 2022, ProQR announced a disappointing outcome for their phase 2/3 trial of sepofarsen for Leber congenital amaurosis type 10 (LCA10).